Yixin Mass Spectrometry Completes Tens of Millions of RMB in Strategic Financing, with T-Capital as Financial Advisor
On October 11, 2021, Yixin Mass Spectrometry completed tens of millions of RMB in strategic financing, invested by E-Town Capital, with T-Capital acting as the financial advisor for this round.
This round of financing revolves around the business development of Yixin Mass Spectrometry in the R&D and production of clinical mass spectrometry systems, providing capital support for the company to further advance its clinical mass spectrometry technology and products.
For medical device and medical technology companies, financing is not only a process of obtaining funds, but also an important strategic link connecting industrial capital, technical capabilities, and future commercialization development.
Transaction Overview
| Item | Information |
|---|---|
| Transaction Date | October 11, 2021 |
| Transaction Type | Strategic Financing |
| Financing Amount | Tens of Millions of RMB |
| Investor | E-Town Capital |
| Financial Advisor | T-Capital |
| Company | Yixin Mass Spectrometry |
| Industry | Medical Devices, Clinical Mass Spectrometry |
| Core Focus | R&D and production of clinical mass spectrometry systems |
I. Yixin Mass Spectrometry: Focusing on the R&D and Production of Clinical Mass Spectrometry Systems
Yixin Mass Spectrometry is the first company in China to focus on the R&D and production of clinical mass spectrometry systems.
The company has long focused on clinical mass spectrometry technology and related medical device products, providing systematic solutions for clinical mass spectrometry detection applications.
In June 2014, Yixin Mass Spectrometry’s independently developed Clin-ToF time-of-flight mass spectrometry system passed medical device certification, making it the first clinical time-of-flight mass spectrometry company in China to obtain a CFDA registration certificate.
This accumulation of products and technology forms an important foundation for the development of Yixin Mass Spectrometry in the clinical mass spectrometry field.
II. Clin-ToF Time-of-Flight Mass Spectrometry System
The Clin-ToF time-of-flight mass spectrometry system, independently developed by Yixin Mass Spectrometry, is an important product in the company’s clinical mass spectrometry technology layout.
According to the company’s technical positioning at the time, the system is oriented towards clinical application scenarios, applying time-of-flight mass spectrometry technology to the field of medical testing.
Compared with traditional single-detection equipment, Yixin Mass Spectrometry has further explored the application of multi-omics testing on a single instrument.
Its goal is to meet the application needs of different clinical testing fields with one device, including:
- Microbial identification;
- Nucleic acid testing;
- Other clinical mass spectrometry-related detection applications.
This technical route enables the mass spectrometry platform to cover a more diverse range of clinical application scenarios.
III. Multi-Omics Testing on a Single Instrument: From Single Detection to Platform Capability
One of the important values of clinical mass spectrometry technology is its ability to support different types of clinical testing using mass spectrometry analysis.
Yixin Mass Spectrometry has achieved multi-omics testing on a single instrument on this basis.
According to information provided by the company, this technology enables one machine to meet the clinical application needs of fields such as microbial identification and nucleic acid testing.
From the perspective of industrial development, this platform-based technical route is of great significance.
For medical institutions, the application range of the equipment, the coverage of testing items, and the utilization rate of the equipment are all factors to be considered when purchasing clinical testing equipment.
Therefore, a technology platform that can cover a variety of testing applications has the opportunity to form a wider range of clinical application scenarios.
IV. Yixin Mass Spectrometry’s Technical Accumulation and Clinical Application Directions
Since its establishment, Yixin Mass Spectrometry has focused on the R&D and production of clinical mass spectrometry systems.
Obtaining the medical device registration certificate for the Clin-ToF time-of-flight mass spectrometry system in 2014 was an important node for its entry into the clinical mass spectrometry market.
Since then, the company has continued to develop products and applications around clinical mass spectrometry technology.
Its core business direction can be summarized as:
Clinical Mass Spectrometry Technology R&D → Medical Device Product Development → Clinical Testing Application.
This business model has the typical characteristics of a medical device technology company.
The company not only needs to continuously conduct technology R&D, but also needs to face multiple links such as medical device registration, clinical application, product production, and market promotion.
V. Industrial Significance of This Strategic Financing
This round of financing was invested by E-Town Capital, with a financing amount of tens of millions of RMB, and T-Capital acted as the financial advisor.
For medical device companies in the stage of technology R&D and industrialization, strategic financing can provide capital support for further development.
At the same time, the participation of industrial capital may also help companies obtain resource connections beyond funding.
For medical device fields with high technical barriers such as clinical mass spectrometry, the development of companies usually requires continuous investment in:
- Product R&D;
- Technology upgrades;
- Medical device registration;
- Production system construction;
- Clinical application promotion;
- Market expansion.
Therefore, the connection between the capital market and industrial resources is an important part of the development process of medical technology companies.
VI. T-Capital Acts as Financial Advisor for This Round
In this strategic financing, T-Capital acted as the financial advisor to Yixin Mass Spectrometry.
Financing for healthcare companies is not just about finding investors.
A complete financing transaction usually needs to be systematically designed around the company’s development stage, financing needs, industrial strategy, and investor matching.
The value of a financial advisor’s work is to help the company connect:
Corporate Value → Financing Strategy → Investor Matching → Transaction Negotiation → Transaction Execution
This is especially important for technology-driven healthcare companies.
The company needs to clearly express to the capital market:
- What are the technical advantages;
- What problem does the product solve;
- Where is the market opportunity;
- What stage of development is the company in;
- What capital is needed in the future;
- What strategic value can investors obtain.
VII. What Should Medical Device Companies Pay Attention to in Financing?
For medical device and medical technology companies, several core issues usually need to be systematically sorted out during the financing process.
1. Technical Value
The company needs to clearly explain what problem the core technology solves and what differentiation it has compared to existing technologies.
2. Product and Registration
Medical device companies need to clarify the product registration, clinical application, and commercialization stages.
3. Market Space
Investors need to understand the target market size, clinical needs, and product application scenarios.
4. Commercialization Capability
Technology ultimately needs to realize commercial value through products and the market, so the commercialization path is also an important part of financing communication.
5. Capital Strategy
Different development stages correspond to different financing needs.
The company needs to consider what problems the current financing solves and what kind of capital and industrial resources are needed in the next stage.
VIII. From a Technology Company to a Healthcare Industry Platform
Clinical mass spectrometry belongs to the intersection of medical testing and medical devices.
With the continuous development of precision medicine, clinical testing, and molecular detection technology, the clinical application of mass spectrometry technology also involves more diverse testing needs.
For technology-based medical device companies, long-term development does not just depend on a single product.
The company also needs to continuously build:
Technology Platform + Product System + Registration Capability + Production Capability + Clinical Application + Commercialization Capability.
Yixin Mass Spectrometry’s long-term layout around the R&D and production of clinical mass spectrometry systems reflects the development path of medical technology companies from core technology to product and industrialization capabilities.
IX. T-Capital: Connecting Healthcare Companies and the Capital Market
T-Capital has a long-term focus on transactions between the healthcare industry and the capital market.
For healthcare companies at different stages of development, capital needs are not the same.
The company may need:
- Private financing;
- Strategic financing;
- Mergers and acquisitions;
- License & BD;
- Strategic cooperation;
- Cross-border transactions.
T-Capital helps healthcare companies sort out their capital needs, find matching investment and industrial cooperation resources, and promote transaction execution through financial advisory and capital transaction services.
X. If Your Company is Looking for Financing or Industrial Capital
Before financing, healthcare companies usually need to answer a core question first:
Does the company now really need funds, or a capital partner that can bring industrial resources, commercialization capabilities, and long-term strategic value?
For innovative drugs, medical devices, medical diagnostics, medical services, AI healthcare, and other healthcare companies, different development stages correspond to different capital strategies.
If your company is considering:
- A new round of equity financing;
- Strategic investment;
- Mergers and acquisitions of healthcare companies;
- Corporate divestitures;
- License-out / License-in;
- Domestic and foreign strategic cooperation;
- Cross-border capital transactions;
T-Capital can assist companies in sorting out capital transaction plans from angles such as transaction structure, investor matching, industrial resources, and transaction execution.
Contact T-Capital
If your company is looking for financing, strategic investment, or industrial cooperation opportunities, you are welcome to communicate with T-Capital.
We are not only concerned with “how much to finance,” but also with helping healthcare companies find capital and industrial partners that match their development stage and long-term strategy.
Business directions include:
- Private Financing
- Mergers & Acquisitions
- License & BD
- Strategic Cooperation
- Cross-border Transactions
Frequently Asked Questions
When did Yixin Mass Spectrometry complete its strategic financing?
Yixin Mass Spectrometry completed this round of tens of millions of RMB in strategic financing on October 11, 2021.
Who is the investor in this round of financing for Yixin Mass Spectrometry?
This round of financing was invested by E-Town Capital.
What role did T-Capital play in this round of financing for Yixin Mass Spectrometry?
T-Capital acted as the financial advisor for this round.
What is Yixin Mass Spectrometry’s main business?
Yixin Mass Spectrometry focuses on the R&D and production of clinical mass spectrometry systems.
What is the Clin-ToF time-of-flight mass spectrometry system?
Clin-ToF is a time-of-flight mass spectrometry system independently developed by Yixin Mass Spectrometry. In June 2014, the system passed medical device certification and became one of the first clinical time-of-flight mass spectrometry companies in China to obtain a CFDA registration certificate.
What is multi-omics testing on a single instrument?
According to information provided by Yixin Mass Spectrometry, multi-omics testing on a single instrument refers to supporting clinical applications in multiple testing fields, including microbial identification and nucleic acid testing, with one device.
Why do medical device companies need financial advisors for financing?
Financing for medical device companies involves multiple links such as corporate value assessment, investor matching, financing structure, business communication, and transaction execution. Professional financial advisors can help companies systematically sort out their financing needs and promote capital transactions.
Which healthcare companies does T-Capital provide capital services for?
T-Capital focuses on the healthcare industry and provides financing, M&A, License & BD, strategic cooperation, and cross-border transaction-related services for companies in fields such as innovative drugs, medical devices, medical diagnostics, medical services, and AI healthcare.